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Abstract
Vaccination, the administration of an antigenic material (vaccine), is considered to be the 
most effective method for disease prevention and control. A vaccine usually contains an 
agent that resembles a diseases‐causing pathogen and is often made from  inactivated 
microbes, live attenuated microbes, its toxins, or part of surface antigens (subunit). 
However, the modern biotechnological tools and genomics have opened a new era to 
develop novel vaccines and many products are successfully marketing around the world. 
It is important to formulate and deliver these vaccines appropriately to maximize the 
potential advances in prevention, therapy, and vaccinology. New vaccines employing 
biotechnological innovations are helping us to change the way for illness prevention. 
The clinical application of vaccines will be diversified along with the development 
of  biotechnologies. In modern society, the outbreak of many infectious diseases has 
decreased through vaccination, but the burden of noninfectious diseases is growing. The 
new biotechnologies may result in not only the appreciation of vaccines which are critical 
in inducing protection against an infectious disease but also the production of thera‐
peutic vaccines which are effective for alldiseases including infectious and noninfectious 
diseases.
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1. Introduction
A vaccine is a biological preparation that provides active acquired immunity to a particular 
pathogen. The agent stimulates the immune system to recognize itself as a foreign threat and 
thus destroys and remembers it, so that the immune system can easily destroy any of these 
pathogens when they later invade into the body. The following vaccine characteristics may be 
altered or enhanced by biotechnologies.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1.1. Type
Inactivated microbes, live attenuated microbes, toxoids, and subunits have been manufac‐
tured as vaccines and employed to trigger adaptive immune responses [1].
1.2. Mode of action
The process is an artificial induction of immunity with an effort to protect against infec‐
tious diseases by priming the immune system with an immunogen. Vaccination traditionally 
includes various ways of administration such as given by injection, oral, intranasal, and per‐
cutaneous administration.
1.3. Effectiveness
The efficacy of vaccines is dependent on a number of factors such as the disease itself, the 
strain of vaccine, the vaccination schedule, idiosyncratic response to vaccination, and assorted 
factors, such as ethnicity, age, or genetic predisposition.
1.4. Potency
The potency is critically correlated to vaccine quality and efficacy. Its assay methods are vari‐
able, including in vivo assay, such as mice challenge test, plaque reduction neutralization test 
(PRNT), and in vitro assay, such as enzyme‐linked immunosorbent assay (ELISA).
1.5. Safety
Vaccines are one of the safest medical products, but they are sometimes risky. The safety 
should be evaluated in clinical phases and postmarket surveillance. Accurate information 
about the value of vaccines as well as their possible side effects helps people to make deci‐
sions about vaccination.
2. Biotechnology
Biotechnology is the technological application of biological organisms, systems, and  processes 
to develop, make, or modify products for specific uses such as pharmaceuticals, crops, and 
livestock. It encompasses a wide range of procedures for modifying living organisms accord‐
ing to human purposes. Traditional methods are the employment of artificial selection and 
hybridization, but modern usage also includes genetic engineering as well as cell and tissue 
culture technologies. In this section, we review some biotechnologies applied for the develop‐
ment and production of vaccines.
2.1. Application
Biotechnology is mainly used in three ways as follows: separation of a pure antigen using a 
specific monoclonal antibody; synthesis of an antigen with the assistance of a cloned gene; 




The basic idea of reverse vaccinology is that an entire pathogenic genome can be sequenced 
and screened by employing bioinformatics methods to explore genes. Functional genom‐
ics approaches, such as DNA microarrays, proteomics, and comparative genome analysis, 
are used for the identification of virulence factors and novel vaccine candidates. This new 
computational approach allows prediction of all antigens, independent of their abundance 
and immunogenicity during infection. The first attempt at reverse vaccinology began with 
Meningococcus B (MenB) vaccine. Moreover, it has been used on several other bacterial vaccines 
such as antibiotic‐resistant Staphylococcus aureus and Streptococcus pneumoniae [2].
Reverse vaccinology have changed the concepts and approaches for vaccine candidate 
selection and design. Genome investigation and selection of antigens provide a new way 
to study the pathogenesis mechanisms. The resulting lists of novel candidates which reveal 
new aspects of pathogenesis will promote the rational design of optimal vaccine antigens. 
Applying genomic approaches to study both hosts and pathogens will ultimately drive and 
guide next‐generation vaccine design [3].
2.2.2. Recombinant subunit vaccination
The gene cloning is a powerful tool to synthesize protein materials to subunit vaccine by 
recombinant DNA techniques. Recombinant subunit vaccines are made from a fragment of 
protein (antigen) expressed in the laboratory using the viral DNA, for example, hepatitis B 
(HB) vaccine. The hepatitis B virus (HBV) gene that codes for the antigen is inserted into 
baker’s yeast genome and then expresses the antigen protein. The antigen protein is harvested 
and purified to be used for the vaccine. This technique is also being used to explore a vaccine 
against hepatitis C [4].
Recombinant‐DNA techniques can facilitate the development of new principles to design 
and produce subunit vaccines. The recombinant subunit vaccine can furthermore be 
adapted by gene‐fusion technology, to be efficiently incorporated into immunopotentiating 
adjuvant systems. The recombinant strategies have become increasingly important to the 
passive vaccination strategy and use antibodies or antibody fragments to prevent infectious 
diseases [5].
2.2.3. Recombinant protein vaccination
Upon infection, a pathogen produces proteins to elicit an immune response from the infected 
body. The gene encoding such a protein is isolated from the causative organism and used 
to develop a recombinant DNA which is expressed in a heterologous expression system 
(e.g., bacterium, yeast, or insect). Recombinant protein vaccines, such as cholera vaccine, 
 diphtheria toxoid, and tetanus toxoid, are composed of protein/toxin antigens that have 
either been produced in another host organism or purified from large amount of pathogens. 
The vaccinated persons produce antibodies to the protein/toxin antigen to protect them‐
selves from diseases.
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The baculovirus‐insect cell expression system is also a recombinant protein manufacturing 
platform for the production of complex proteins. The technology is used for the mass produc‐
tion of various recombinant protein vaccines. The major advantage is that a universal “plug 
and play” process may be used to produce a variety of protein‐based prophylactic and thera‐
peutic vaccines for human uses [6].
2.2.4. Deoxyribonucleic acid (DNA) vaccination
DNA vaccination is a technique for protecting against diseases through the direct injection 
of genetically engineered DNA. The gene responsible for the immunogenic protein is cloned 
with a corresponding expression vector. This DNA will trigger an immune response and the 
individual is successfully vaccinated. DNA vaccines may have the ability to induce a wider 
range of immune response types over conventional vaccines.
Despite several DNA vaccines are available for veterinary uses, none of them is commercial 
for human uses. Research is being investigated using the approach for controlling infectious 
diseases and several cancers in humans. For instance, a synthetic consensus antispike protein 
DNA vaccine induces protective immunity against Middle East respiratory syndrome (MERS) 
coronavirus in nonhuman primates [7]. The improved formulations and delivery methods 
can increase the uptake of vaccine plasmids by cells. The optimization of vaccine vectors and 
encoded antigens, and the adding of novel adjuvants potentially increase and direct the host 
immune responses. Therefore, current DNA vaccines may induce more potent, cellular, and 
humoral immune responses to be tested for both preventative and therapeutic uses [8].
2.2.5. Messenger ribonucleic acid (mRNA) vaccination
mRNA vaccines consist of mRNA, which is encoded by antigen genes of an infectious agent. 
When the mRNA is administered into host cells, it will translate protein antigens that elicit 
protective immunity against the infectious agent [9]. Vaccines based on mRNA may offer 
a solution as sequence‐matched, clinical‐grade material could allow quick responses to the 
emergence of pandemic microbe strains.
mRNA vaccines have an outstanding safety profile and the unmet genetic flexibility. mRNA 
vaccines can induce a balanced immune response comprising both cellular and humoral 
immunity. Compared with DNA vaccines, mRNA offers stronger safety advantages in which 
it harbors only the elements directly required for expression of the encoded protein and 
hardly interacts with the genome [10]. Because any protein can be encoded and expressed by 
mRNA without the need to adjust the production process, mRNA vaccines offer maximum 
flexibility with respect to vaccine production, and principally enable the development of pro‐
phylactic and therapeutic vaccines fighting against infections and cancers [10].
2.3. Advantages
(1) Low risk for infection: Recombinant vaccines do not contain actual pathogens; only parts 
of the microbes (DNA, RNA, or protein) are used for making vaccines. Thus, recombinant 
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vaccines are safer than conventional vaccines and can be given to people with weakened 
immune systems.
(2) Induction of more efficient immunity: Recombinant vaccines potentially induce both hu‐
moral and cellular immune responses to result in more effective vaccination.
2.4. Challenges
(1) Complex vaccination schedules: The vaccines produced by biotechnologies are usually 
only parts of microbes (DNA, RNA, or protein); therefore, it is required to have multiple 
doses for maximum effectiveness either to produce sufficient initial immune responses or 
to boost responses that fade over time. To achieve full immunity, several doses must be 
given to induce additional “booster” shots for proper long‐term immunity.
(2) Economics: The research and development (R&D) of vaccines using biotechnologies is risky, 
costly, and time consuming. Most pharmaceutical firms and vaccine manufacturers have 
little incentive to develop vaccines based on biotechnologies because of limited revenue.
3. Products
Many products based on biotechnologies have been successfully marketing in many countries 
for years (Table 1).
3.1. Hepatitis B virus (HBV) vaccine: Recombivax HB®, Engerix‐B®, Elovac B®, 
Genevac B®, and Shanvac B®
The vaccine is designed to prevent hepatitis B and currently produced with recombinant DNA 
techniques. It contains one of the viral envelope proteins‐hepatitis B surface antigens (HBsAg) 
and produced in yeast cells, into which the genetic code for HBsAg has been inserted. The 
Product Recombivax HB®, 
Engerix B®, Elovac 









HBV Rotavirus HPV Dengue virus Neisseria meningitidis 
group B strain
Indication Hepatitis B Gastroenteritis Cervical cancer Dengue Meningitis
Vaccine type Subunit vaccine Live attenuated 
vaccine
Subunit vaccine Live attenuated 
vaccine
Subunit vaccine
Administration IM Oral IM IM IM
Human papilloma virus (HPV); hepatitis B virus (HBV); and intramuscular injection (IM).
Table 1. Vaccine products based on biotechnologies (recombinant DNA technology).
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antigen is harvested and purified from fermentation cultures of a recombinant strain of the 
yeast Saccharomyces cerevisiae containing the gene for the adw subtype of HBsAg [11, 12].
3.2. Rotavirus vaccine: Rotarix® and RotaTeq®
This vaccine is designed to protect against rotavirus infections that cause vomiting and severe 
diarrhea in infants and children. It contains live attenuated viruses and should not be given 
to people who are clinically immunosuppressed. Rotarix® is a monovalent and indicated for 
the prevention of rotavirus gastroenteritis caused by G1 and non‐G1 types (G3, G4, and G9). 
RotaTeq® is a pentavalent vaccine that contains five rotavirus strains produced by reassort‐
ment. Four reassortant rotaviruses express one of the outer capsid, VP7, proteins (serotypes 
G1, G2, G3, or G4) from the human rotavirus parent strain and the attachment protein VP4 
(type P7) from the bovine rotavirus parent strain [13, 14].
3.3. Human papilloma virus (HPV) vaccine: Gardasil® and Cervarix®
The vaccine is designed to prevent infection by certain types of HPV. HPV vaccines are sub‐
unit vaccines containing virus‐like particles (VLPs) assembled from the major capsid protein 
(L1 protein) of HPV type 6, 11, 16, and 18 (GardasilTM) and type 16 and 18 (CervarixTM). 
Available vaccines protect against two or four types of HPV; however, all vaccines protect 
against at least HPV 16 and 18 that cause the greatest risk of cervical cancer. The L1 proteins 
of these HPV types (16 and 18) are separately produced using a recombinant baculovirus 
expression system and the insect cell line [15, 16].
3.4. Dengue vaccine: Dengvaxia® (CYD‐TDV)
The vaccine is designed to induce an immune system to produce antibodies against four sero‐
types of dengue (DENV‐1, 2, 3, and 4) and a live attenuated tetravalent chimeric vaccine using 
recombinant DNA technology by replacing the pre‐membrane (PrM) and envelope (E) struc‐
tural genes of the yellow fever live attenuated vaccine. For the vaccine, the virus is geneti‐
cally engineered to include genes encoding for dengue proteins. Its production is based on a 
weakened combination of the yellow fever virus and each of the four virus serotypes [17–19].
3.5. Men B (Neisseria meningitidis group B strain) vaccine: Bexsero® and Trumenba®
The vaccine is indicated for active immunization to prevent invasive disease caused by 
Neisseria meningitidis serogroup B. The vaccine is manufactured using recombinant DNA 
technology (rDNA, component, adsorbed) and includes four antigenic proteins: Neisseria 
heparin binding antigen (NHBA), Neisserial adhesion A (NadA), Factor H binding protein 
(fHbp) and PorA to protect against the majority of circulating MenB strains [20].
4. Perspectives
In this section, we describe some trends for the development of vaccines using  biotechnologies 
(Figure 1).
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4.1. Enlargement of protective groups
Most vaccines were focusing on infants and children, but adolescents and adults are grad‐
ually being targeted. During the course of their lives, adolescents and adults may need 
vaccination when they are hurt, sick, and pregnant or take a tour to some disease‐endemic 
area. In addition, hospital patients, pregnant women, volunteer workers, individual 
with noninfectious diseases, and individual with chronic infections may need to prevent 
 diseases necessarily than healthy persons; therefore, they will be the new target group for 
vaccination.
Figure 1. The perspectives of vaccine products based on biotechnologies.
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4.2. Development of combination vaccines
Combination vaccines include two or more vaccines that could be given individually or by 
combining them together into one shot. People get the same protection with fewer shots, 
compared with individual vaccines given separately. Fewer shots means less pain and stress 
for the people, especially for infants and children. For example, infants and children may only 
get one shot to protect him from three or even five diseases, instead of three or five individ‐
ual shots. Diphtheria, tetanus, and pertussis (DTP) vaccine and measles, mumps and rubella 
(MMR) vaccine are two successful combination vaccines [21]. Also, combining vaccines make 
more infants and children get recommended vaccinations on schedule. Because scientists are 
developing more combination vaccines against more diseases, combination vaccines may 
become more common in the near future.
4.3. Development of multiple administration routes
Most of the vaccines are given by injection such as intramuscular (IM), subcutaneous (SC), and 
intradermal (ID) injection. Additionally, mouths and nostrils are two successful alternative 
routes for administration. For example, Sabin vaccine (OPV) and FluMist® are given by oral 
administration and intranasal spray, respectively. These two methods are more effective, inex‐
pensive, painless, and convenient than injection. Microparticles introduced by biotechnologies 
have made it possible to have an inactive Vibrio cholera whole‐cell vaccine that changes its admin‐
istration route from injection to oral administration in mice [22]. Furthermore, more methods of 
administering vaccines through biotechnologies are being developed including patches, aerosol 
inhalation, microneedles, and even eating of genetically modified organisms (GMO).
4.4. Development of synthetic vaccines
Synthetic vaccines are composed mainly of synthetic peptides, polysaccharides, or antigens. 
They are usually considered to be safer than vaccines from bacterial cultures, because they 
are developed by reconstructing the outside structure of a microbe, which helps to prevent 
vaccine resistance. Diphtheria toxoid is the first synthetic vaccine which was created in 1982. 
Creating vaccines synthetically can expedite a specific vaccine production [23]. This is particu‐
larly important in the outbreak of a pandemic disease.
4.5. Development of vaccines for both innate and adaptive immunity
Conventional vaccines only induce adaptive immunity, but vaccines are being designed to 
stimulate both innate and adaptive immune responses. This can be accomplished by the addi‐
tion of an appropriate adjuvant such as CpG oligonucleotides [24].
4.6. Development of vaccines for preventing noninfectious diseases
Conventional vaccines are only used to prevent infectious diseases in which active immuni‐
zation is largely confined to infectious diseases. However, vaccines are being developed to 
prevent many noninfectious human diseases such as cancer, type I diabetes mellitus (T1DM), 
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Alzheimer disease and drug addiction, etc. Mostly efforts are being directed against cancers. 
It has been very successful in reducing the incidence of hepatoma and cervical cancer using 
of HBV and HPV vaccines for preventing virus infection. Several types of preventive can‐
cer vaccines are being tried such as antigen vaccines, tumor cell vaccines, dendritic vaccines, 
DNA vaccines, and viral vector vaccines [25]. Tolerization to autoantigens is being attempted 
in T1DM; the administration of diabetes‐specific autoantigens can elicit tolerance, which can 
prevent the destruction of β‐cells [26]. Alzheimer disease may be controlled by immunization 
against amyloid [27]. It is known that drug addictions (e.g. cocaine) may be controllable by 
inducing antibodies that rapidly remove the drugs from the body [28]. Recent studies further 
reveal that the activation of Toll‐like receptor 9 (TLR9) can improve the function of cocaine 
vaccines in the presence of TLR5 activation [29].
4.7. Development of vaccines for therapy
Vaccines are conventionally prophylactic, but vaccines are being developed to treat chronic 
virus infection and cancer.
(1) Chronic virus infection: The induction of cellular immune response can suppress chronic 
virus infections such as HBV, hepatitis C virus (HCV), human immunodeficiency virus 
(HIV), and HPV [30].
(2) Cancer: Some cancers are difficult to treat by conventional methods such as surgery, radi‐
ation, chemotherapy, and target therapy, but can be controlled by the immune responses 
triggered by cancer vaccines. However, the development of these therapeutic vaccines 
is extremely challenging. Fortunately, expanded studies and knowledge regarding the 
mechanisms how cancer cells escape the immune system may develop new means in 
modulating the immune responses to cancer; thus, potentially enhancing the effective‐
ness of therapeutic cancer vaccines.
4.8. Development of vaccines for bioterrorism
Bioterrorist attack is unpleasant and rare, but it may happen unexpectedly and often leads to 
serious events. It is needed to develop vaccines to defend against bioterrorism agents such as 
anthrax, plague, smallpox, and even severe acute respiratory syndromes (SARS). Such vac‐
cines must provide protection against pathogens that might enter the body by a variety of 
routes including the oral and respiratory tract. They should be given by noninvasive routes 
and able to induce protective immunity rapidly. The design of improved vaccines is likely to 
rely on the genome information of bioterrorism agents that have either completed or have 
almost completed sequencing [31].
5. Discussion
The development of powerful biotechnological tools applied to genome‐based approaches 
has virtually revolutionized vaccine development. The information of genome provides a list 
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of all the potential proteins from which it is possible for scientists to select some antigens or 
antigenic materials that are likely to be more effective vaccines [25]. Even if biotechnologies 
render many benefits for vaccine development, they are not always advantageous. The dis‐
advantages include limited immunization to antigens, risk of affecting genes controlling cell 
growth, possibility of inducing antibody production against DNA, possibility of tolerance to 
the antigen produced, and potential for atypical processing of microbial proteins. In addition, 
it is a critical issue to formulate and deliver these vaccines appropriately to improve vaccine 
quality and expand their clinical application.
Vaccines dramatically reduce the incidence of serious infectious diseases and allow life expec‐
tancy of people to gradually increase. The persistent outbreak of many infectious diseases 
has decreased through vaccination; however, the burden of noninfectious diseases such as 
cancers, cardiovascular diseases, and diabetes mellitus has increased. This transformation of 
disease burden has indicated that the need for vaccines to treat or prevent noninfectious dis‐
eases is urgent. Both infectious and noninfectious diseases are now within the realm of vaccin‐
ology through the development of biotechnologies. Noninfectious disease vaccines also can 
be made by biotechnologies, but their target is human normal cells or abnormal cells, rather 
than pathogens or pathogen‐infected cells. These vaccines present an interesting challenge for 
approving and evaluating under the same framework as traditional vaccines or that of other 
biologics, though they work by modulating the human immune system as traditional vac‐
cines. Noninfectious disease vaccines have raised the question of whether the term “vaccine” 
is appropriate and some regulatory implications for this new category of drugs.
Despite vaccine development is rapid and clinical application is significantly expanded by 
biotechnologies, some infections, including HIV, HCV, SARS, MERS, Ebola virus, cytomeg‐
alovirus, and Zika virus, are under research and there are no effective vaccines available 
yet. Many vaccine candidates for these infections had been developed, but none had been 
approved for use in humans. The major difficulty for their clinical application is the lack of 
human clinical trials, the data insufficiency of for vaccine effectiveness, and the concern of 
vaccine safety. More funding, time, and research are needed for developing vaccines against 
recent emerging diseases such as MERS, Ebola virus, Zika virus infections, etc.
The perspectives for controlling diseases by vaccination are very promising along with the 
advancement of biotechnologies, but several problems are still hard to solve. First, vaccine 
supply is not sufficient even in the highly‐developed countries, shortage of vaccines may occur 
due to regulatory pressures on production and the lack of qualified manufacturers. In the case 
of emergency, such as an influenza pandemic, it is difficult to estimate the demand of vaccine 
to satisfy the developing countries. Second, new vaccine discovery is very expensive and most 
of the manufacturers which do R&D have to pay the cost, but its revenue is limited. Some 
manufacturers may change their focusing products from vaccines to other medicinal products 
such as cell therapy products, gene therapy products, nanomedicines, and other products. 
Third, the requirement for vaccine safety is increasing, the evaluation of risk and benefit ratios 
become very crucial for the implementation of a vaccination program. But zero risk is almost 
impossible. It is quite difficult and controversial to obtain a balance between the need of public 
health and the regulatory impulse which guard against rare and theoretical risks.
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6. Conclusion
Vaccination is the best approach to prevent infectious diseases. Vaccination is able to 
reduce the rates of mortality and morbidity from infection and results in herd immunity 
when some population has been vaccinated in some areas. Through vaccines distribu‐
tion, some diseases are globally eradicated such as smallpox; some diseases are signifi‐
cantly controlled in much of the world such as polio, measles, and tetanus. However, there 
are many diseases uncontrolled yet by vaccination, and new diseases certainly appear 
through evolution, mutation, gene recombination, interspecies transfer, and environmen‐
tal changes. Fortunately, we have many technologies to produce more novel vaccines to 
protect us. The previous studies have allowed us to understand the microbial pathogenesis 
and host immune responses which are correlated to the control of diseases by vaccination. 
Biotechnologies make it possible to further improve the quality of vaccines and expand 
the clinical application of vaccines significantly. More and more novel vaccine products 
based on biotechnologies are approved in the market around the world. Despite the great 
advances in biotechnologies, the perfect vaccine has not yet been developed. This vaccine 
would be temperature insensitive, multivalent and induce specific immunity against the 
protective antigens, would prevent and treat both diseases and possibly infections, would 
have long‐term immunity without booster doses, free of adverse reactions, and adminis‐
tered without needles and the help of trained health workers. It is expectable to have such 
effective, cheap, and convenient vaccines for disease prevention and therapy provided that 
we endeavor to overcome the challenges in the production, distribution, and regulation of 
vaccines through biotechnologies.
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